ImQuest to file IND of anti-HIV drug

Published: 2008-07-17 06:41:00

Updated: 2008-07-17 06:41:00

ImQuest Pharmaceuticals Inc. expects to submit an IND in the United States to initiate Phase 1 human clinical trials with IQP·0410, a highly potent member of the pyrimidinedione series in the third quarter of 2008, according to Samjin Pharm.

ImQuest licensed entire series of anti-HIV therapeut...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK